Researchers from University of California Los Angeles have developed a ready-to-use novel immunotherapy for endometrial cancer that could eventually be used for ovarian, breast, pancreatic and lung cancers in the future.
The team has published its findings on using chimeric antigen receptors invariant natural killer T cells — or CAR-NKT cells — against aggressive endometrial cancer subtypes Jan. 29 in Experimental Hematology & Oncology.
“CAR-NKT cells are produced from donated blood stem cells in a scalable process, and because NKT cells are naturally compatible with any immune system, a single donation can yield enough cells for thousands of treatments,” according to a March 16 news release from the UCLA Health.
“The idea is to pre-make the product, cryopreserve it and have it ready to go as soon as the patient needs the therapy,” co-senior author Lili Yang, PhD, a professor of microbiology, immunology and molecular genetics at UCLA, said in the release.
The research team is preparing to submit clinical trial applications to the FDA, the release said.
